CD44-binding ligands
AssigneeDyax Corp.
InventorsIsaac J. Rondon, Albert Edge, Rachel Baribault Kent
Life of this patent
Estimating the term…
Abstract
The invention provides, inter alia, CD44-binding proteins, including CD4-binding antibodies, antibody fragments, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such proteins. Methods of using the proteins to detect CD44 or to modulate a CD44-expressing cell, e.g., in a subject, are also described.
Claims41
An isolated protein comprising a light chain (LC) immunoglobulin variable domain sequence and a heavy chain (HC) immunoglobulin variable domain sequence,
- wherein the LC and HC variable domain sequences form an antigen binding site with binding affinity for the human CD44 extracellular domain and wherein CDR3 of the LC variable domain sequence comprises M-Q-A-L-Q-X1—P—X2-T, where X1 is threonine or absent, and X2 is any amino acid or absent.
An isolated protein comprising a light chain (LC) immunoglobulin variable domain sequence and a heavy chain (HC) immunoglobulin variable domain sequence,
- wherein the LC and HC variable domain sequences form an antigen binding site with affinity for the human CD44 extracellular domain, and
- each of CDR1, CDR2, and CDR3 of at least one the variable domain sequences by no more than two amino acid differences from a respective CDR of the HAE-B8 antibody.
An isolated protein comprising a light chain (LC) immunoglobulin variable domain sequence and a heavy chain (HC) immunoglobulin variable domain sequence,
- wherein the LC and HC variable domain sequences form an antigen binding site with affinity for the human CD44 extracellular domain, and
- each of CDR1, CDR2, and CDR3 of at least one the variable domain sequences by no more than two amino acid differences from a respective CDR of the HAE-F1 antibody.
An isolated protein comprising a light chain (LC) immunoglobulin variable domain sequence and a heavy chain (HC) immunoglobulin variable domain sequence,
- wherein the LC and HC variable domain sequences form an antigen binding site with affinity for the human CD44 extracellular domain, and
- each of CDR 1, CDR2, and CDR3 of at least one the variable domain sequences by no more than two amino acid differences from a respective CDR of the BE-A11 antibody.
An isolated protein comprising a heavy chain immunoglobulin variable domain sequence and a light chain immunoglobulin variable domain sequence, wherein the protein binds to CD44 ectodomain with a Kd of less than 2×10−7 M and comprises at least two human CDRs.
Dependencies are inferred from the claim text.